First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

被引：22

作者：

O'Donnell, Peter H.

Balar, Arjun Vasant

Vuky, Jacqueline

Castellano, Daniel

Bellmunt, Joaquim

Powles, Thomas

Bajorin, Dean F.

Grivas, Petros

Hahn, Noah M.

Plimack, Elizabeth R.

Xu, Jin Zhi

Godwin, James Luke

Moreno, Blanca Homet

De Wit, Ronald

机构：

[1] Univ Chicago, Chicago, IL 60637 USA

[2] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA

[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[4] Hosp Univ 12 Octubre, Madrid, Spain

[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA

[6] Queen Mary Univ London, Barts Canc Inst, London, England

[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[8] Univ Washington, Seattle, WA 98195 USA

[9] Johns Hopkins Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[10] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Erasmus MC Canc Inst, Rotterdam, Netherlands

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.4508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4508

引用

页数：3

共 50 条

[41] Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial
Fradet, Yves
Bellmunt, Joaquim
De Wit, Ronald
Vaughn, David J.
Lee, Jae-Lyun
Fong, Lawrence
Vogelzang, Nicholas J.
Climent, Miguel A.
Petrylak, Daniel Peter
Choueiri, Toni K.
Necchi, Andrea
Gerritsen, Winald R.
Gurney, Howard
Quinn, David I.
Culine, Stephane
Sternberg, Cora N.
Nam, Kijoeng
Frenkl, Tara L.
Perini, Rodolfo F.
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[42] Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study.
Frenel, Jean-Sebastien
Le Tourneau, Christophe
O'Neil, Bert H.
Ott, Patrick Alexander
Piha-Paul, Sarina Anne
Gomez-Roca, Carlos Alberto
Van Brummelen, Emilie
Rugo, Hope S.
Thomas, Shari
Saraf, Sanatan
Chen, Mei
Varga, Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[43] Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
Llovet, Josep M.
Kudo, Masatoshi
Cheng, Ann-Lii
Finn, Richard S.
Galle, Peter R.
Kaneko, Shuichi
Meyer, Tim
Qin, Shukui
Dutcus, Corina E.
Chen, Erluo
Dubrovsky, Leonid
Zhu, Andrew X.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[44] Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
Kato, K.
Sun, J-M.
Shah, M. A.
Enzinger, P. C.
Adenis, A.
Doi, T.
Kojima, T.
Metges, J-P.
Li, Z.
Kim, S-B.
Cho, B. C. Chul
Mansoor, W.
Li, S-H.
Sunpaweravong, P.
Maqueda, M. A.
Goekkurt, E.
Liu, Q.
Shah, S.
Bhagia, P.
Shen, L.
ANNALS OF ONCOLOGY, 2020, 31 : S1192 - S1193
[45] Biomarker analysis of first-line sintilimab plus gemcitabine and cisplatin in patients with advanced biliary tract cancers: Results from a phase II study.
Yuan, Zhen-Gang
Zeng, Tian-Mei
Tao, Chen-Jie
Yang, Guang
Xu, He-Ming
Wei, Wei
Chen, Xi-Yun
Cheng, Zhuo
Dong, Yu-Long
Shang, Pei-Pei
Lou, Cheng
Han, Qin
Chen, Dong-Sheng
Song, Yunjie
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16189 - E16189
[46] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Rha, S. Y.
Wyrwicz, L. S.
Weber, P. E. Y.
Bai, Y.
Ryu, M. H.
Lee, J.
Rivera, F.
Alves, G. V.
Garrido, M.
Shiu, K. -k.
Fernandez, M. Gonzalez
Li, J.
Lowery, M.
Cil, T.
Cruz, F. J. S. M.
Qin, S.
Yin, L.
Bordia, S.
Bhagia, P.
Oh, D-y.
ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
[47] Second-line (2L) pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Three-year follow up (FU) of the phase 1 KEYNOTE-151 study.
Guo, Jun
Zhang, Xiaoshi
Shu, Yongqian
Pan, Hongming
Wu, Di
Liu, Jiwei
Mao, Lili
Wang, Xuan
Wen, Xizhi
Gu, Yanhong
Zhu, Lingjun
Lan, Shijie
Cai, Xin
Diede, Scott J.
Dai, Haiyan
Niu, Cuizhen
Si, Lu
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).
Bellmunt, Joaquim
De Wit, Ronald
Vaughn, David J.
Fradet, Yves
Lee, Jae-Lyun
Fong, Lawrence
Vogelzang, Nicholas J.
Climent, Miguel A.
Petrylak, Daniel Peter
Choueiri, Toni K.
Necchi, Andrea
Gerritsen, Winald
Gurney, Howard
Quinn, David I.
Culine, Stephane
Sternberg, Cora N.
Nam, Kijoeng
Frenkl, Tara L.
Perini, Rodolfo F.
Bajorin, Dean F.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[49] Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)
Necchi, A.
Fradet, Y.
Bellmunt, J.
de Wit, R.
Lee, J-L.
Fong, L.
Vozelgang, N. J.
Climent, M. A.
Petrylak, D. P.
Choueiri, T. K.
Gerritsen, W. R.
Gurney, H.
Quinn, D. I.
Culine, S.
Sternberg, C. N.
Nam, K.
Frenkl, T. L.
Godwin, J. L.
Bajorin, D. F.
Vaughn, D. J.
ANNALS OF ONCOLOGY, 2019, 30 : 366 - +
[50] Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up
Gupta, Shilpa
Rosenberg, Jonathan E.
Mckay, Rana R.
Flaig, Thomas W.
Petrylak, Daniel P.
Hoimes, Christopher J.
Friedlander, Terence W.
Bilen, Mehmet Asim
Srinivas, Sandy
Burgess, Earle F.
Merchan, Jaime R.
Tagawa, Scott T.
Brown, Jason R.
Yu, Yao
Carret, Anne-Sophie
Wirtz, Heidi
Guseva, Maria
Moreno, Blanca Homet
Milowsky, Matthew I.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →